| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
8,190,000 |
| Market
Cap: |
17.36(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.6001 - $3.95 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Indaptus Therapeutics is a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, which Co. refers to as the Accordion Pill. Co.'s primary product candidate, Accordion Pill Carbidopa/Levodopa is being developed for the indication of treatment of Parkinson's disease symptoms in Parkinson's disease patients. In addition, Co. has initiated a clinical development program for its Accordion Pill platform with the two primary cannabinoids contained in cannabis sativa, which it refers to as AP-Cannabinoids. Co. is formulating and testing Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
103,352 |
154,229 |
| Total Buy Value |
$0 |
$0 |
$216,389 |
$343,091 |
| Total People Bought |
0 |
0 |
1 |
4 |
| Total Buy Transactions |
0 |
0 |
3 |
12 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Anderson Glen R. |
10% Owner |
– – • |
2023-08-14 |
4 |
B |
$2.34 |
$56,006 |
I/I |
23,934 |
1,190,400 |
1.5 |
-26% |
|
| Anderson Glen R. |
10% Owner |
– – • |
2023-08-11 |
4 |
B |
$2.12 |
$74,336 |
I/I |
35,064 |
1,166,466 |
1.5 |
-20% |
|
| Anderson Glen R. |
10% Owner |
– – • |
2023-08-10 |
4 |
B |
$1.94 |
$86,047 |
I/I |
44,354 |
1,131,402 |
1.5 |
-15% |
|
| Litchev Boyan Vesselinov |
Chief Medical Officer |
• – – |
2022-12-01 |
4 |
B |
$1.87 |
$935 |
D/D |
500 |
1,150 |
2.66 |
2% |
|
| Litchev Boyan Vesselinov |
Chief Medical Officer |
• – – |
2022-11-22 |
4 |
B |
$1.83 |
$915 |
D/D |
500 |
650 |
2.66 |
-2% |
|
| Meckler Jeffrey A |
CEO and Director |
• • – |
2022-11-21 |
4 |
B |
$1.90 |
$18,240 |
D/D |
9,600 |
75,374 |
2.81 |
- |
|
| Meckler Jeffrey A |
CEO and Director |
• • – |
2022-11-18 |
4 |
B |
$1.76 |
$705 |
D/D |
400 |
65,774 |
2.73 |
2% |
|
| Meckler Jeffrey A |
CEO and Director |
• • – |
2022-09-08 |
4 |
B |
$2.80 |
$28,862 |
D/D |
10,308 |
65,374 |
2.81 |
-38% |
|
| Linscott Walt Addison |
Chief Business Officer |
• – – |
2022-09-07 |
4 |
B |
$2.62 |
$393 |
D/D |
150 |
150 |
2.66 |
-39% |
|
| Meckler Jeffrey A |
CEO and Director |
• • – |
2022-09-07 |
4 |
B |
$2.57 |
$22,184 |
D/D |
8,632 |
55,066 |
2.81 |
-39% |
|
| Meckler Jeffrey A |
CEO and Director |
• • – |
2022-09-06 |
4 |
B |
$2.44 |
$2,586 |
D/D |
1,060 |
46,434 |
2.73 |
-35% |
|
| Anderson Glen R. |
10% Owner |
– – • |
2022-06-27 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
973,130 |
|
-12% |
|
| Anderson Glen R. |
10% Owner |
– – • |
2022-06-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
113,918 |
|
-12% |
|
| Meckler Jeffrey A |
CEO and Director |
• • – |
2022-06-06 |
4 |
B |
$2.63 |
$51,882 |
D/D |
19,727 |
45,374 |
2.81 |
-32% |
|
| Litchev Boyan Vesselinov |
Chief Medical Officer |
• – – |
2022-03-02 |
4 |
B |
$4.09 |
$205 |
D/D |
50 |
150 |
2.66 |
-25% |
|
| Newman Michael James |
CSO and Director |
• • • |
2022-02-01 |
4 |
AS |
$5.00 |
$70,692 |
I/I |
(14,130) |
1,368,356 |
|
-46% |
|
| Litchev Boyan Vesselinov |
Chief Medical Officer |
• – – |
2022-01-31 |
4 |
B |
$4.65 |
$465 |
D/D |
100 |
100 |
2.66 |
-46% |
|
| Newman Michael James |
CSO and Director |
• • • |
2022-01-31 |
4 |
AS |
$5.00 |
$29,351 |
I/I |
(5,870) |
1,382,486 |
|
-46% |
|
| Meckler Jeffrey A |
CEO and Director |
• • – |
2021-11-18 |
4 |
B |
$5.82 |
$65,108 |
D/D |
11,187 |
25,647 |
2.81 |
-28% |
|
| Meckler Jeffrey A |
CEO and Director |
• • – |
2021-09-14 |
4 |
B |
$7.00 |
$84,000 |
D/D |
12,000 |
14,460 |
2.81 |
-32% |
|
| Lee Hoonmo |
Director |
– • • |
2021-08-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
694,522 |
|
- |
|
| Newman Michael James |
Chief Scientific OfficerOffice |
• • • |
2021-08-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,388,356 |
|
- |
|
| Maddaluna Anthony J |
Director |
– • – |
2021-07-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
670 |
|
- |
|
| Meckler Jeffrey A |
Chief Executive OfficerOfficer |
• • – |
2021-07-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,460 |
|
- |
|
24 Records found
|
1
|
Page 1 of 1 |
|
|
0.03 (1.4%) 
